After reconstitution, vials should be refrigerated and protected from light, with use within the expiration timeframe indicated by the supplier
Phase 3 trials of CagriSema demonstrated: 15.6% body weight loss with the combination versus 8.1% with semaglutide alone Superior glycemic control compared to either component individually Manageable side effect profile with proper dose titration Regulatory submissions completed in 2024 for obesity treatment [6] Since retatrutide includes GLP-1 receptor activation (similar to semaglutide) plus additional GIP and glucagon receptor effects, the theoretical cagrilintide blend with retatrutide could potentially exceed even the impressive CagriSema results
However, the IM route was the top-ranked statistically, followed by the SL and then the oral routes, but without clinical significance
I've referred a friend and she is having a great experience too
Contraindications to Semaglutide include: a personal history of pancreatitis, alcohol abuse, renal impairment, uncontrolled psychiatric disorders, personal or family history of medullary thyroid carcinoma (MTC), or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and if you are pregnant or breastfeeding
Avoid vendors hiding testing details